Associations between metabolic syndrome and gynecologic cancer
3
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Metabolic syndrome (MetS) is a group of risk factors that causes cardiovascular and diabetic morbidity and mortality,which is diagnosed by central obesity, dyslipidemia, hyperglycemia, and hypertension. Increasing epidemiological dataand experimental results indicate that the presence of MetS increases the incidence of common malignancies andrelated mortality. Epidemiological studies have previously reported an association of endometrial cancer occurrencewith MetS. Aromatization of androstenedione to estrogen, insulin resistance, and diabetes can cause increased levelsof free estrogen, and the detrimental effect of elevated estrogen as a carcinogen is well studied in endometrialcancer. Medications used to manage MetS such as metformin and statins are suggested to reduce endometrial cancerrisk and improve survival. Some large population-based epidemiological studies have suggested that the MetS isrelated to an increased risk of cervical carcinoma. MetS may contribute to viral-host interactions, which lead topersistent human papilloma virus (HPV) infection, although limited epidemiological data are available. Specific effectsof obesity and diabetes on the occurrence of ovarian cancer have been suggested. However, the direct correlationbetween MetS and ovarian cancer is still lacking. Previous retrospective studies reported that the use of metformin,statins, and beta-blockers could be associated with cancer prevention or better prognosis. Proper diagnosis andmanagement of the MetS should be a part of the strategies undertaken to prevent and treat gynecologic cancer. Sofar, only limited data is available on this subject, and further clinical and fundamental research is required to furtherclarify the effect of these therapies on gynecologic cancer treatment.
Abstract
Metabolic syndrome (MetS) is a group of risk factors that causes cardiovascular and diabetic morbidity and mortality,which is diagnosed by central obesity, dyslipidemia, hyperglycemia, and hypertension. Increasing epidemiological dataand experimental results indicate that the presence of MetS increases the incidence of common malignancies andrelated mortality. Epidemiological studies have previously reported an association of endometrial cancer occurrencewith MetS. Aromatization of androstenedione to estrogen, insulin resistance, and diabetes can cause increased levelsof free estrogen, and the detrimental effect of elevated estrogen as a carcinogen is well studied in endometrialcancer. Medications used to manage MetS such as metformin and statins are suggested to reduce endometrial cancerrisk and improve survival. Some large population-based epidemiological studies have suggested that the MetS isrelated to an increased risk of cervical carcinoma. MetS may contribute to viral-host interactions, which lead topersistent human papilloma virus (HPV) infection, although limited epidemiological data are available. Specific effectsof obesity and diabetes on the occurrence of ovarian cancer have been suggested. However, the direct correlationbetween MetS and ovarian cancer is still lacking. Previous retrospective studies reported that the use of metformin,statins, and beta-blockers could be associated with cancer prevention or better prognosis. Proper diagnosis andmanagement of the MetS should be a part of the strategies undertaken to prevent and treat gynecologic cancer. Sofar, only limited data is available on this subject, and further clinical and fundamental research is required to furtherclarify the effect of these therapies on gynecologic cancer treatment.
참고문헌 (71)
- Alberti KG, "Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute;American Heart Association; World Heart Federation;International Atherosclerosis Society; and International Association for the Study of Obesity", Circulation, 120, pp.1640~1645 (2009)
- Hong AR, "Clinical characteristics of metabolic syndrome in Korea, and its comparison with other Asian countries", J Diabetes Investig, 6, pp.508~515 (2015)
- Cowey S, "The metabolic syndrome : a highrisk state for cancer?", Am J Pathol, 169, pp.1505~1522 (2006)
- Renehan AG, "Body-mass index and incidence of cancer : a systematic review and meta-analysis of prospective observational studies", Lancet, 371, pp.569~578 (2008)
- 이석우, "폐경 후 여성에서 혈청 렙틴 농도와 대사증후군과의 관계", Obstetrics & Gynecology Science, 53(03), pp.254~263 (2010), 대한산부인과학회
- van Kruijsdijk RC, "Obesity and cancer : the role of dysfunctional adipose tissue", Cancer Epidemiol Biomarkers Prev, 18, pp.2569~2578 (2009)
- Reeves GK, "Cancer incidence and mortality in relation to body mass index in the Million Women Study : cohort study", BMJ, 335, pp.1134~ (2007)
- Calle EE, "Overweight, obesity and cancer : epidemiological evidence and proposed mechanisms", Nat Rev Cancer, 4, pp.579~591 (2004)
- Iyengar NM, "Obesity and cancer : local and systemic mechanisms", Annu Rev Med, 66, pp.297~309 (2015)
- Yager JD, "Estrogen carcinogenesis in breast cancer", N Engl J Med, 354, pp.270~282 (2006)
- Flötotto T, "Hormones and hormone antagonists : mechanisms of action in carcinogenesis of endometrial and breast cancer", Horm Metab Res, 33, pp.451~457 (2001)
- Dickson RB, "Chapter 8 : Estrogen receptormediated processes in normal and cancer cells", JNCI Monogr, 2000, pp.135~145 (2000)
- Carmichael AR, "Obesity and prognosis of breast cancer", Obes Rev, 7, pp.333~340 (2006)
- 지선하, "Obesity, Insulin Resistance and Cancer Risk", Yonsei Medical Journal, 46(4), pp.449~455 (2005), 연세대학교의과대학
- Iyengar NM, "Obesity and cancer mechanisms : tumor microenvironment and inflammation", J Clin Oncol, 34, pp.4270~4276 (2016)
- Macheda ML, "Molecular and cellular regulation of glucose transporter(GLUT)proteins in cancer", J Cell Physiol, 202, pp.654~662 (2005)
- Iwatsuki M, "Epithelial-mesenchymal transition in cancer development and its clinical significance", Cancer Sci, 101, pp.293~299 (2010)
- Masur K, "Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation", Br J Cancer, 104, pp.345~352 (2011)
- Ulmer H, "Serum triglyceride concentrations and cancer risk in a large cohort study in Austria", Br J Cancer, 101, pp.1202~1206 (2009)
- Tulinius H, "Risk factors for malignant diseases : a cohort study on a population of 22, 946 Icelanders", Cancer Epidemiol Biomarkers Prev, 6, pp.863~873 (1997)
- Gaard M, "Risk of breast cancer in relation to blood lipids : a prospective study of 31, 209 Norwegian women", Cancer Causes Control, 5, pp.501~509 (1994)
- Penaranda EK, "Relationship between metabolic syndrome and history of cervical cancer among a US national population", ISRN Oncol, 2013, pp.840964~ (2013)
- Kucharska-Newton AM, "HDL-cholesterol and incidence of breast cancer in the ARIC cohort study", Ann Epidemiol, 18, pp.671~677 (2008)
- Esposito K, "Metabolic syndrome and endometrial cancer : a meta-analysis", Endocrine, 45, pp.28~36 (2014)
- Trabert B, "Metabolic syndrome and risk of endometrial cancer in the united states : a study in the SEERmedicare linked database", Cancer Epidemiol Biomarkers Prev, 24, pp.261~267 (2015)
- Ko EM, "The complex triad of obesity, diabetes and race in type I and II endometrial cancers : prevalence and prognostic significance", Gynecol Oncol, 133, pp.28~32 (2014)
- Forney JP, "Aromatization of androstenedione to estrone by human adipose tissue in vitro. Correlation with adipose tissue mass, age, and endometrial neoplasia", J Clin Endocrinol Metab, 53, pp.192~199 (1981)
- Wallace IR, "Sex hormone binding globulin and insulin resistance", Clin Endocrinol(Oxf), 78, pp.321~329 (2013)
- Fader AN, "Endometrial cancer and obesity : epidemiology, biomarkers, prevention and survivorship", Gynecol Oncol, 114, pp.121~127 (2009)
- Evans JM, "Metformin and reduced risk of cancer in diabetic patients", BMJ, 330, pp.1304~1305 (2005)
- Wu JW, "Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality : a review of the literature", Expert Opin Drug Saf, 13, pp.1071~1099 (2014)
- Zhang ZJ, "The prognostic value of metformin for cancer patients with concurrent diabetes : a systematic review and meta-analysis", Diabetes Obes Metab, 16, pp.707~710 (2014)
- Rattan R, "Metformin : an emerging new therapeutic option for targeting cancer stem cells and metastasis", J Oncol, 2012, pp.928127~ (2012)
- Cantrell LA, "Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy", Gynecol Oncol, 116, pp.92~98 (2010)
- Kourelis TV, "Metformin and cancer : new applications for an old drug", Med Oncol, 29, pp.1314~1327 (2012)
- Hanna RK, "Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway", Gynecol Oncol, 125, pp.458~469 (2012)
- Gazzerro P, "Pharmacological actions of statins : a critical appraisal in the management of cancer", Pharmacol Rev, 64, pp.102~146 (2012)
- Martirosyan A, "Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin : potential therapeutic relevance", BMC Cancer, 10, pp.103~ (2010)
- Horiuchi A, "Overexpression of RhoA enhances peritoneal dissemination : RhoA suppression with Lovastatin may be useful for ovarian cancer", Cancer Sci, 99, pp.2532~2539 (2008)
- Lavie O, "The effect of statins on risk and survival of gynecological malignancies", Gynecol Oncol, 130, pp.615~619 (2013)
- Lacey JV Jr, "Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix", Cancer, 98, pp.814~821 (2003)
- Ulmer H, "Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project(Me-Can)", Gynecol Oncol, 125, pp.330~335 (2012)
- Chung SH, "Estrogen and ERα : culprits in cervical cancer?", Trends Endocrinol Metab, 21, pp.504~511 (2010)
- Baker R, "Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection", Cytokine, 53, pp.282~285 (2011)
- Huang X, "Metabolic syndrome and risk of cervical human papillomavirus incident and persistent infection", Medicine(Baltimore), 95, pp.e2905~ (2016)
- Molokwu JC, "Association of metabolic syndrome and human papillomavirus infection in men and women residing in the United States", Cancer Epidemiol Biomarkers Prev, 26, pp.1321~1327 (2017)
- Liu SH, "Excessive adiposity, metabolic health, and risks for genital human papillomavirus infection in adult women : a population-based cross-sectional study", BMC Obes, 2, pp.39~ (2015)
- 소경아, "Risk factors for cytological progression in HPV 16 infected women with ASC-US or LSIL: The Korean HPV cohor", Obstetrics & Gynecology Science, 61(6), pp.662~668 (2018), 대한산부인과학회[DOI]
- Kemp TJ, "Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection", Cancer Epidemiol Biomarkers Prev, 19, pp.1954~1959 (2010)
- Bárdos JI, "Negative and positive regulation of HIF-1 : a complex network", Biochim Biophys Acta, 1755, pp.107~120 (2005)
- Bodily J, "Persistence of human papillomavirus infection : keys to malignant progression", Trends Microbiol, 19, pp.33~39 (2011)
- Serrano ML, "Cervical scrapes levels of insulin-like growth factor-II and insulinlike growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer", Horm Metab Res, 42, pp.977~981 (2010)
- Ahn HK, "Metabolic components and recurrence in early-stage cervical cancer", Tumour Biol, 36, pp.2201~2207 (2015)
- Collaborative Group on Epidemiological Studies of Ovarian Cancer, "Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies", PLoS Med, 9, pp.e1001200~ (2012)
- Ma X, "Anthropometric measures and epithelial ovarian cancer risk among Chinese women : results from the Shanghai Women's Health Study", Br J Cancer, 109, pp.751~755 (2013)
- Olsen CM, "Obesity and risk of ovarian cancer subtypes : evidence from the Ovarian Cancer Association Consortium", Endocr Relat Cancer, 20, pp.251~262 (2013)
- Protani MM, "Obesity and ovarian cancer survival: a systematic review and meta-analysis", Cancer Prev Res(Phila), 5, pp.901~910 (2012)
- Diaz ES, "Obesity-associated adipokines correlate with survival in epithelial ovarian cancer", Gynecol Oncol, 129, pp.353~357 (2013)
- Pavelka JC, "Effect of obesity on survival in epithelial ovarian cancer", Cancer, 107, pp.1520~1524 (2006)
- 배효숙, "The Effect of Body Mass Index on Survival in Advanced Epithelial Ovarian Cancer", Journal of Korean Medical Science, 29(6), pp.793~797 (2014), 대한의학회
- Son JH, "A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer", J Obstet Gynaecol Res, 44, pp.1294~1301 (2018)
- Shah MM, "Diabetes mellitus and ovarian cancer : more complex than just increasing risk", Gynecol Oncol, 135, pp.273~277 (2014)
- Nieman KM, "Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth", Nat Med, 17, pp.1498~1503 (2011)
- Laws MJ, "Dysregulated estrogen receptor signaling in the hypothalamic-pituitary-ovarian axis leads to ovarian epithelial tumorigenesis in mice", PLoS Genet, 10, pp.e1004230~ (2014)
- Dilokthornsakul P, "The effects of metformin on ovarian cancer : a systematic review", Int J Gynecol Cancer, 23, pp.1544~1551 (2013)
- Gotlieb WH, "In vitro metformin anti-neoplastic activity in epithelial ovarian cancer", Gynecol Oncol, 110, pp.246~250 (2008)
- Sood AK, "Stress hormone-mediated invasion of ovarian cancer cells", Clin Cancer Res, 12, pp.369~375 (2006)
- Lutgendorf SK, "Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines", Clin Cancer Res, 9, pp.4514~4521 (2003)
- Barron TI, "Beta blockers and breast cancer mortality : a population-based study", J Clin Oncol, 29, pp.2635~2644 (2011)
- Powe DG, "Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival", Oncotarget, 1, pp.628~638 (2010)
- Diaz ES, "Impact of beta blockers on epithelial ovarian cancer survival", Gynecol Oncol, 127, pp.375~378 (2012)